Pfizer Market Cap 2010-2025 | PFE

Pfizer market cap history and chart from 2010 to 2025. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Pfizer market cap as of July 11, 2025 is $145.83B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $145.830B $63.627B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $751.564B 57.63
Johnson & Johnson (JNJ) United States $377.513B 15.61
AbbVie (ABBV) United States $339.944B 18.74
Novo Nordisk (NVO) Denmark $307.772B 20.39
Roche Holding AG (RHHBY) Switzerland $258.243B 0.00
Novartis AG (NVS) Switzerland $255.645B 14.60
Merck (MRK) United States $209.320B 10.70
Sanofi (SNY) France $119.214B 11.74
Bayer (BAYRY) Germany $31.359B 6.38
Innoviva (INVA) United States $1.178B 12.35